Why use it

Wheezing in early childhood is extremely common (~40% of children wheeze at some point before age 6) but does not consistently predict later asthma. The mAPI allows clinicians to stratify wheezing toddlers by risk of persistent asthma, guiding decisions about early controller therapy, allergy evaluation, environmental modification, and parental counseling. The PEAK trial demonstrated that ICS therapy in mAPI-positive children reduced exacerbations during treatment but did not prevent asthma onset after stopping — indicating mAPI identifies a phenotype, not necessarily a reversible process.

About

The Modified Asthma Predictive Index (mAPI) is a clinical prediction tool developed to identify young children with recurrent early-life wheezing who are likely to develop persistent asthma by school age. The original Asthma Predictive Index (API) was published by Castro-Rodriguez and colleagues in 2000 using data from the Tucson Children's Respiratory Study. The modified version (mAPI) was subsequently refined, most notably by Guilbert et al. in the PEAK (Prevention of Early Asthma in Kids) trial (2006), which used the mAPI as the primary enrollment criterion. The mAPI is applied to children ≤3 years of age who have experienced ≥4 wheezing episodes in the past year, at least one of which was physician-diagnosed. A positive mAPI requires meeting at least 1 major criterion OR at least 2 minor criteria. A positive mAPI is associated with significantly increased risk of asthma by ages 6–13 (positive predictive value ~50%, negative predictive value ~95% — a negative mAPI largely reassures against school-age asthma).

When to use

Children ≤3 years of age with ≥4 wheezing episodes in the past year (at least 1 physician-diagnosed)
Stratifying wheezing infants and toddlers by future asthma risk for counseling and management planning
Deciding whether early daily ICS controller therapy is warranted in a wheezing young child
Guiding referral to allergist/pulmonologist in high-risk children
Enrollment criteria evaluation for clinical trials of early asthma intervention
NOT intended for children >5 years — at that age, standard spirometry and clinical asthma criteria apply

Formula

ELIGIBILITY: Age ≤3 years AND ≥4 wheezing episodes in the past year (≥1 physician-diagnosed) MAJOR CRITERIA (≥1 required for positive mAPI): 1. Parental history of asthma (biological parent with physician-diagnosed asthma) 2. Physician-diagnosed atopic dermatitis in the child 3. Sensitization to ≥1 aeroallergen (positive specific IgE or skin prick test) MINOR CRITERIA (≥2 required for positive mAPI if no major criteria): 1. Sensitization to cow's milk, egg, or peanut 2. Wheezing episodes unrelated to colds 3. Peripheral blood eosinophilia ≥4% (from CBC differential) POSITIVE mAPI: ≥1 major criterion OR ≥2 minor criteria NEGATIVE mAPI: 0 major criteria AND 0–1 minor criteria

Pearls & pitfalls

The mAPI requires ≥4 wheezing episodes in the past year with at least 1 physician-diagnosed — it is NOT applicable to children with only 1–3 wheezing episodes.
A negative mAPI has a very high negative predictive value (~95%) — a mAPI-negative child is unlikely to have school-age asthma.
Physician-diagnosed atopic dermatitis is a major criterion — it must be formally diagnosed (not parent-reported "eczema") for consistent application.
Aeroallergen sensitization (major criterion): includes house dust mite, cat, dog, cockroach, mold, tree/grass pollens — any one positive specific IgE (≥0.35 kU/L) or positive skin prick test qualifies.
Food sensitization (minor criterion): milk, egg, or peanut — positive specific IgE or skin prick test.
Peripheral eosinophilia ≥4% (minor criterion): from a CBC differential — a common and easily obtained test.
Wheezing apart from colds (minor criterion): distinguishes atopic wheeze from pure viral-triggered wheeze. Parents can usually distinguish between wheeze only with infections vs. wheeze in clear intervals.
The mAPI does NOT predict which children will outgrow asthma or respond to specific therapies — it identifies risk, not certainty.
ICS therapy in mAPI-positive children: the PEAK trial (Guilbert 2006) showed benefit during treatment years (fewer exacerbations, better lung function) but no disease modification after stopping — do not overinterpret ICS as curative.

Next steps

Positive mAPI (≥1 major OR ≥2 minor criteria): Significant risk for school-age asthma (~50% PPV). Consider: allergy testing (skin prick test or specific IgE) for aeroallergens and foods; environmental allergen modification; discussion of early ICS controller therapy for frequent episodic or persistent symptoms; referral to allergist/pulmonologist. Negative mAPI: Low asthma risk (~95% NPV). Reassurance appropriate. Continue monitoring. Episodic bronchodilator therapy for wheeze episodes. Negative mAPI does NOT exclude viral-triggered wheeze — continue as-needed SABA for episodes.

Evidence

Castro-Rodriguez JA et al. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000;162(4):1403-1406. PMID:11029352. Guilbert TW et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985-1997. PMID:16687711. Leonardi NA et al. Validity of the modified Asthma Predictive Index for early identification of asthma. Eur Respir J. 2011;37(2):384-391.

References

Castro-Rodriguez JA et al. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000;162(4):1403-1406. — link
Guilbert TW et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985-1997. — link
Leonardi NA et al. Validity of the modified Asthma Predictive Index for early identification of asthma. Eur Respir J. 2011;37(2):384-391. — link

Modified Asthma Predictive Index (mAPI)

Calculator